Please wait while the formulary information is being retrieved.
Drug overview for DULCOLAX (BISACODYL) (bisacodyl):
Generic name: bisacodyl (bis-AK-oh-dil)
Drug class: Stimulant Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Diphenylmethane laxatives (e.g., bisacodyl) are stimulant laxatives.
No enhanced Uses information available for this drug.
Generic name: bisacodyl (bis-AK-oh-dil)
Drug class: Stimulant Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Diphenylmethane laxatives (e.g., bisacodyl) are stimulant laxatives.
No enhanced Uses information available for this drug.
DRUG IMAGES
DULCOLAX EC 5 MG TABLET
The following indications for DULCOLAX (BISACODYL) (bisacodyl) have been approved by the FDA:
Indications:
Constipation
Professional Synonyms:
None.
Indications:
Constipation
Professional Synonyms:
None.
The following dosing information is available for DULCOLAX (BISACODYL) (bisacodyl):
The recommended dosages of the diphenylmethane laxatives should not be exceeded.
Bisacodyl is administered orally. Bisacodyl also is administered rectally as a suppository or enema. Bisacodyl tannex is administered rectally as an enema.
For occasional use as an oral laxative, bisacodyl should be administered the evening before a morning bowel movement is desired. Rectal bisacodyl suppositories and enemas may be administered at the time a bowel movement is desired. To avoid gastric irritation and the possibility of vomiting, enteric-coated bisacodyl tablets must be swallowed whole and not crushed, chewed, or taken within 1 hour of antacids or milk.
For occasional use as an oral laxative, bisacodyl should be administered the evening before a morning bowel movement is desired. Rectal bisacodyl suppositories and enemas may be administered at the time a bowel movement is desired. To avoid gastric irritation and the possibility of vomiting, enteric-coated bisacodyl tablets must be swallowed whole and not crushed, chewed, or taken within 1 hour of antacids or milk.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DULCOLAX EC 5 MG TABLET | Maintenance | Adults take 2 tablets (10 mg) by oral route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BISACODYL EC 5 MG TABLET | Maintenance | Adults take 2 tablets (10 mg) by oral route once daily |
| RA BISACODYL EC 5 MG TABLET | Maintenance | Adults take 2 tablets (10 mg) by oral route once daily |
| CVS BISACODYL EC 5 MG TABLET | Maintenance | Adults take 2 tablets (10 mg) by oral route once daily |
| GS BISACODYL EC 5 MG TABLET | Maintenance | Adults take 2 tablets (10 mg) by oral route once daily |
The following drug interaction information is available for DULCOLAX (BISACODYL) (bisacodyl):
There are 0 contraindications.
There are 3 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Selected Bowel Preparations/Stimulant Laxatives SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Osmotic laxatives and stimulant laxatives may have additive adverse effects.(1) CLINICAL EFFECTS: Concurrent use of stimulant laxatives and Sutab tablets (sodium sulfate, magnesium sulfate, and potassium chloride) may increase the risk of mucosal ulceration, ischemic colitis, gastric ulcerations, or gastritis.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of Sutab tablets (sodium sulfate, magnesium sulfate and potassium chloride) recommends avoiding the use of stimulant laxatives while using this bowel preparation product.(1) DISCUSSION: Osmotic laxative products may produce colonic mucosal aphthous ulcerations which reports have shown can lead to ischemic colitis requiring hospitalization. Using stimulant laxatives in addition may increase this risk.(1) |
SUFLAVE, SUTAB |
| Trofinetide/Laxatives SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Trofinetide commonly causes diarrhea of mild to moderate severity. Laxatives may increase the incidence or severity of diarrhea.(1) CLINICAL EFFECTS: Concurrent use of laxatives with trofinetide may increase the risk of severe diarrhea.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should stop laxatives before starting trofinetide. If diarrhea occurs, consider anti-diarrheal treatment and monitor hydration status. If severe diarrhea or dehydration occurs, interrupt, reduce dose, or discontinue trofinetide.(1) DISCUSSION: In clinical trials, 85% of patients on trofinetide developed diarrhea. Concurrent use of laxatives may increase this risk.(1) |
DAYBUE |
| Tenapanor/Laxatives; Stool Softeners SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Tenapanor commonly causes diarrhea of mild to moderate severity. Laxatives and stool softeners may increase the incidence or severity of diarrhea.(1) CLINICAL EFFECTS: Concurrent use of laxatives or stool softeners with tenapanor may increase the risk of severe diarrhea.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of tenapanor states that patients should be instructed to avoid stool softeners and laxatives with tenapanor. If severe diarrhea occurs, tenapanor should be discontinued.(1) DISCUSSION: In clinical trials, 43-53% of CKD patients on dialysis treated with tenapanor developed diarrhea. Diarrhea usually occurred soon after treatment initiation and was severe in 5% of patients.(1) |
XPHOZAH |
There are 0 moderate interactions.
The following contraindication information is available for DULCOLAX (BISACODYL) (bisacodyl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Appendicitis |
| Gastrointestinal obstruction |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Fecal incontinence |
The following adverse reaction information is available for DULCOLAX (BISACODYL) (bisacodyl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 4 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dehydration |
| Rare/Very Rare |
|---|
|
Disorder of electrolytes Syncope Ulceration of colon |
There are 7 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abdominal pain with cramps Diarrhea Dizziness Eructation Headache disorder Nausea |
| Rare/Very Rare |
|---|
|
Urine discoloration |
The following precautions are available for DULCOLAX (BISACODYL) (bisacodyl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DULCOLAX (BISACODYL) (bisacodyl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for DULCOLAX (BISACODYL) (bisacodyl)'s list of indications:
| Constipation | |
| K59.0 | Constipation |
| K59.00 | Constipation, unspecified |
| K59.01 | Slow transit constipation |
| K59.03 | Drug induced constipation |
| K59.04 | Chronic idiopathic constipation |
| K59.09 | Other constipation |
Formulary Reference Tool